This report details cases of macrolide-resistant Mycoplasma pneumoniae infections in children in Ohio, USA. Patients presented with respiratory symptoms, and the pathogen was identified through molecular methods. The findings highlight the increasing prevalence of macrolide resistance in Mycoplasma pneumoniae, complicating treatment choices for pediatric respiratory infections. This resistance necessitates careful consideration of diagnostic stewardship and alternative therapeutic strategies, such as fluoroquinolones, especially in cases unresponsive to standard macrolide therapy. Continued surveillance is crucial to monitor resistance patterns and guide clinical management.
Key note: The emergence of macrolide-resistant Mycoplasma pneumoniae in children complicates empirical treatment, underscoring the need for resistance surveillance and alternative therapies.